NO880247L - Nye isoksazolderivater samt fremgangsmaate for fremstilling av disse. - Google Patents
Nye isoksazolderivater samt fremgangsmaate for fremstilling av disse.Info
- Publication number
- NO880247L NO880247L NO880247A NO880247A NO880247L NO 880247 L NO880247 L NO 880247L NO 880247 A NO880247 A NO 880247A NO 880247 A NO880247 A NO 880247A NO 880247 L NO880247 L NO 880247L
- Authority
- NO
- Norway
- Prior art keywords
- general formula
- methyl
- hydrogen
- compounds
- stands
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 230000000840 anti-viral effect Effects 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 150000002545 isoxazoles Chemical class 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- BQGDYNKJFVSETN-UHFFFAOYSA-N 5-[7-[5-(4,4-dimethyl-5h-1,3-oxazol-2-yl)thiophen-2-yl]oxyheptyl]-3-methyl-1,2-oxazole Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCC(C)(C)N=2)S1 BQGDYNKJFVSETN-UHFFFAOYSA-N 0.000 claims description 3
- 230000002924 anti-infective effect Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- ZWZUFCDJXCQDCR-UHFFFAOYSA-N 3-methyl-5-[7-[5-(4-methyl-4,5-dihydro-1,3-oxazol-2-yl)thiophen-2-yl]oxyheptyl]-1,2-oxazole Chemical compound CC1COC(C=2SC(OCCCCCCCC=3ON=C(C)C=3)=CC=2)=N1 ZWZUFCDJXCQDCR-UHFFFAOYSA-N 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 15
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 5
- 239000007758 minimum essential medium Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- WBWVCVIGPNKPAT-UHFFFAOYSA-N 5-[7-(3-methyl-1,2-oxazol-5-yl)heptoxy]thiophene-2-carboxylic acid Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C(O)=O)S1 WBWVCVIGPNKPAT-UHFFFAOYSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- HEMWTUWIGAKRSF-UHFFFAOYSA-N n-(1-hydroxy-2-methylpropan-2-yl)-5-[7-(3-methyl-1,2-oxazol-5-yl)heptoxy]thiophene-2-carboxamide Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C(=O)NC(C)(C)CO)S1 HEMWTUWIGAKRSF-UHFFFAOYSA-N 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- -1 etc. Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 231100000567 intoxicating Toxicity 0.000 description 1
- 230000002673 intoxicating effect Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical class C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT16487 | 1987-01-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO880247D0 NO880247D0 (no) | 1988-01-21 |
| NO880247L true NO880247L (no) | 1988-07-29 |
Family
ID=3483261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO880247A NO880247L (no) | 1987-01-28 | 1988-01-21 | Nye isoksazolderivater samt fremgangsmaate for fremstilling av disse. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US4841065A (cs) |
| EP (1) | EP0280017A1 (cs) |
| JP (1) | JPS63201186A (cs) |
| KR (1) | KR880009017A (cs) |
| AU (1) | AU604085B2 (cs) |
| CS (1) | CS268697B2 (cs) |
| DD (1) | DD267491A5 (cs) |
| DK (1) | DK39388A (cs) |
| FI (1) | FI880357A7 (cs) |
| HU (1) | HU203235B (cs) |
| IL (1) | IL85134A0 (cs) |
| MY (1) | MY102282A (cs) |
| NO (1) | NO880247L (cs) |
| NZ (1) | NZ223256A (cs) |
| ZA (1) | ZA8867B (cs) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8807275D0 (en) * | 1988-03-26 | 1988-04-27 | Synphar Lab Inc | Chemical compounds |
| US5859035A (en) * | 1996-04-03 | 1999-01-12 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
| KR100747002B1 (ko) | 2005-02-26 | 2007-08-07 | 주식회사 엘지생명과학 | 이소옥사졸린 유도체 및 그의 제조 방법 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4451476A (en) * | 1982-12-13 | 1984-05-29 | Sterling Drug Inc. | Isoxazoles as antiviral agents |
| NZ209209A (en) * | 1983-08-29 | 1988-02-12 | Sterling Drug Inc | Substituted phenyl-aliphatic isoxazole derivatives and pharmaceutical compositions |
| FI83782C (fi) * | 1985-05-17 | 1991-08-26 | Chemie Linz Ag | Foerfarande foer framstaellning av farmakologiskt vaerdefulla substituerande isoxazolderivat. |
-
1987
- 1987-12-28 MY MYPI87003256A patent/MY102282A/en unknown
-
1988
- 1988-01-06 ZA ZA880067A patent/ZA8867B/xx unknown
- 1988-01-11 US US07/142,677 patent/US4841065A/en not_active Expired - Fee Related
- 1988-01-14 EP EP88100441A patent/EP0280017A1/de not_active Withdrawn
- 1988-01-19 IL IL85134A patent/IL85134A0/xx unknown
- 1988-01-21 NZ NZ223256A patent/NZ223256A/xx unknown
- 1988-01-21 CS CS88405A patent/CS268697B2/cs unknown
- 1988-01-21 NO NO880247A patent/NO880247L/no unknown
- 1988-01-26 DD DD88312440A patent/DD267491A5/de unknown
- 1988-01-26 JP JP63013742A patent/JPS63201186A/ja active Pending
- 1988-01-27 KR KR1019880000615A patent/KR880009017A/ko not_active Withdrawn
- 1988-01-27 HU HU88338A patent/HU203235B/hu not_active IP Right Cessation
- 1988-01-27 AU AU10769/88A patent/AU604085B2/en not_active Ceased
- 1988-01-27 DK DK039388A patent/DK39388A/da not_active Application Discontinuation
- 1988-01-27 FI FI880357A patent/FI880357A7/fi not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| FI880357L (fi) | 1988-07-29 |
| DK39388D0 (da) | 1988-01-27 |
| JPS63201186A (ja) | 1988-08-19 |
| AU604085B2 (en) | 1990-12-06 |
| NO880247D0 (no) | 1988-01-21 |
| CS40588A2 (en) | 1989-07-12 |
| FI880357A0 (fi) | 1988-01-27 |
| ZA8867B (en) | 1988-06-27 |
| HUT50171A (en) | 1989-12-28 |
| NZ223256A (en) | 1990-08-28 |
| DD267491A5 (de) | 1989-05-03 |
| KR880009017A (ko) | 1988-09-13 |
| HU203235B (en) | 1991-06-28 |
| FI880357A7 (fi) | 1988-07-29 |
| AU1076988A (en) | 1988-08-04 |
| DK39388A (da) | 1988-07-29 |
| IL85134A0 (en) | 1988-06-30 |
| MY102282A (en) | 1992-05-15 |
| CS268697B2 (en) | 1990-04-11 |
| US4841065A (en) | 1989-06-20 |
| EP0280017A1 (de) | 1988-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1950376B (zh) | 莪术醇衍生物、含该衍生物的组合物及所述衍生物的制药用途 | |
| KR870001027B1 (ko) | 카르복시이미드 유도체의 제조방법 | |
| KR101419320B1 (ko) | 2-(치환된-아미노)-벤조티아졸 설폰아미드 ｈｉｖ 프로테아제 저해제 | |
| EP0261442A1 (en) | Malonic acid derivatives | |
| ITMI950812A1 (it) | Pirril-(indolil)-aril-sulfoni e relativo processo di produzione ed impiego nella terapia delle infezioni da virus dell'aids | |
| US20100022527A1 (en) | Biphenyl substituted spirotetronic acids and their use for the treatment of retroviral diseases | |
| US5681832A (en) | Aroylaniline compounds, pharmaceutical compositions, and methods of using same to inhibit viral activity | |
| NO880247L (no) | Nye isoksazolderivater samt fremgangsmaate for fremstilling av disse. | |
| KR0165108B1 (ko) | 디벤즈[b,f][1,4]옥사제핀(및 티아제핀)-11(10H)-온 및 -티온을 포함하는 사람 면역 결핍 바이러스(HIV)-1 감염 예방 또는 치료용 약제학적 조성물 | |
| HK87696A (en) | Indolyl propanols, process for their preparation, their uses and preparation containing them | |
| US4812472A (en) | Isoxazole compounds and pharmaceutical compositions containing them for treatment and prophylaxis of retroviruses diseases | |
| NL7905855A (nl) | Immunostimulerende n-gesubstitueerde aziridine 2-carbonzuurderivaten, werkwijze ter bereiding daarvan, alsmede geneesmiddelen, die deze verbindingen bevatten. | |
| EP2029526B1 (en) | Lysine related derivatives as hiv aspartyl protease inhibitors | |
| IE913898A1 (en) | The use of thiazoloisoindolinone derivatives as antiviral¹medicaments | |
| WO2002059123A2 (en) | Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds | |
| WO2002055520A2 (en) | Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds | |
| JPS63215624A (ja) | ピロリドン誘導体およびその用途 | |
| US3814762A (en) | 4-thiosemicarbazido-5-pyrimidine-carboxylic acid alkyl esters | |
| NZ199917A (en) | 1,3,4-thiadiazoles | |
| EA016060B1 (ru) | Производные аминофенилсульфонамида в качестве ингибиторов протеазы вич | |
| KR880000450B1 (ko) | 카르복시이미드 유도체의 제조방법 | |
| FI105680B (fi) | Menetelmä terapeuttisesti käyttökelpoisten hydroksialkylideenisyaanietikkahappoamidien valmistamiseksi | |
| KR880000451B1 (ko) | 카르복시이미드 유도체의 제조방법 | |
| JPS62145060A (ja) | ピペラジン誘導体及びその製法 | |
| JPS61140593A (ja) | 新規ベンジルホスフイン酸エステル誘導体、その製造法およびそれを有効成分とする医薬組成物 |